Who Owns C4 Therapeutics Stock?
NASDAQ: CCCCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 103.30%
- Institutions (% of float)
- 104.18%
- Held by insiders
- 0.84%
- Institutional holders
- 200
- Institutions 99.2%
- Insiders 0.8%
- Public and other 0.0%
Who owns C4 Therapeutics stock?
Institutional investors own about 103.3% of C4 Therapeutics's shares, spread across 200 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.84% of CCCC.
The largest institutional holders are Morgan Stanley (7.21%), RA Capital Management, L.P. (6.50%) and Blackrock Inc. (6.42%). Together, the top 10 institutions control 51.5% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their CCCC positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CCCC
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Morgan Stanley | 8.87M | 7.21% | -2.3% |
| RA Capital Management, L.P. | 8.00M | 6.50% | 0.0% |
| Blackrock Inc. | 7.90M | 6.42% | +285.5% |
| Lynx1 Capital Management Lp | 7.33M | 5.96% | +4.7% |
| Squadron Capital Management LLC | 7.20M | 5.85% | +220.0% |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 5.83% | 0.0% |
| JPMORGAN CHASE & CO | 4.75M | 3.86% | +47.3% |
| Vanguard Capital Management LLC | 4.42M | 3.59% | +14.4% |
| Citadel Advisors Llc | 4.19M | 3.40% | +66.8% |
| Goldman Sachs Group Inc | 3.53M | 2.87% | +47.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CCCC
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.26M | 2.65% |
| iShares Trust-iShares Russell 2000 ETF | 2.56M | 2.08% |
| WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | 2.50M | 2.04% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.11M | 0.90% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 1.05M | 0.85% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05M | 0.85% |
| iShares Trust-iShares Russell 2000 Value ETF | 921.96K | 0.75% |
| iShares Trust-iShares Biotechnology ETF | 837.99K | 0.68% |
| WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | 761.87K | 0.62% |
| JNL Series Trust-JNL MULTI-MANAGER SMALL CAP VALUE FUND | 633.78K | 0.52% |
Frequently asked questions
Who is the largest shareholder of C4 Therapeutics?
Morgan Stanley is the largest institutional shareholder of CCCC, owning 7.21% of shares outstanding (8.87M shares) as of its latest 13F filing.
What percentage of C4 Therapeutics is owned by institutions?
Institutions own about 103.3% of CCCC shares and 104.2% of the public float.
How much of C4 Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.84% of CCCC shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.